In each case the two critical determinants to the success or failure of each new compound as a viable product were safety and efficacy. Such data ultimately can only come from trials in patients. However, this must always be preceded by evaluations of safety in animals. It is the role of clinical chemistry in the assessment of drug safety in laboratory animals that is the subject of this commentary.
of chemicals and drugs, too numerous to mention here. However, all include elements of screening, determination of target-organ toxicity, assignment of safe dosages, and use of multiple species. These questions are central to formulation of a benefit/risk ratio, and to the probability of successful extrapolation of it to man.
The most important differences between clinical chemical analysis performed during animal and safety assessment testing and that seen in usual hospital practice are (a) groups of animals are available at a variety of treatment levels, including a non-medicated control group, such that mean values for each variable or factor measured become available for comparison and statistical evaluation; (b) relatively small changes in the analytes measured are the rule rather than the exception; (c) pre-dose baselines are available for each animal being tested; and, finally, (d) postmortem examination and histological evaluation of the tissues of animals receiving the compound under test are included, so that changes in bloodchemical values and the cellular response of organs can be closely compared.
One of the most challenging areas of clinical chemistry in drug and chemical safety testing is the identification and interpretation of small but clinically meaningful biochemical changes. Modern instrumentation and highly refmed methods have reduced the analytical-variation component of many tests to a small fraction of the intra-individual variation (3). In a setting in which uniformity of animals, housing, and diet substantially reduce biological random variation, in which there is carefully timed serial sampling, and in which there is strong clinical interest in assessing doses that have "no effect," high analytical precision has an enormous impact on the interpretation of results.
With several concurrent sample groups for comparison, with target-organ toxicity anticipated in at least a general way, and with clear-cut dose relationships to changing values expected, the inherent sensitivity of a given test can easily approach the maximum or boundary conditions in which day-to-day changes within the same individual will not be obscured by analytical error. In a general sense this represents a highly desirable situation. However, it also requires a complete species-by-species reappraisal of the biological relevance of small changes in concentration of blood constituents.
Biological Changes
In human clinical evaluations, changes in concentrations of blood constituents are generally considered important if they deviate from the so-called "normal range" by two-or three-fold. For example, the Expert Panel on Enzymes of the Gastrointestinal Advisory Committee to the Food and Drug Administration has recommended that aspartate and alanine aminotransferase activities must be at least threefold normal before being considered presumptive evidence of liver disease (4). It is clear that in most cases such massive changes in relatively tightly controlled blood constituents are accompanied by gross pathological changes encompassing greater than 50% of the target organ (5-7). Oral dosing of male rats with 50mg of thioacetamide per kilogram body weight for one day produces centrolobular liver necrosis involving 80-90% of the lobule. There are acute changes in activity of serum aspartate and alanine aminotransferases and lactate dehydrogenase, nearly 10-fold the baseline values. However, and much more importantly, intake of as little as 5 mg of thioacetamide per kilogram body weight in the rat produces morphological changes involving less than 5% of the liver, which are accompanied by small but statistically significant changes in mean serum enzyme activity (8) .
Under the controlled conditions of a safety-evaluation study, concentrations of serum constituents can be compared to prior stable baseline data and concurrent controls. For example, dogs receiving doses of phenytoin within the therapeutic range exhibit very early increases in serum alkaline phosphatase of osseous origin, months before clinical signs of osteomalacia appear (9). Often these increases amount to no more than about 15-20%, too small to be considered important in ordinary hospital practice, but certainly detectable, reproducible, and statistically significant as compared to controls. Likewise, small but reproducible increases in serum electrolytes have been found in dogs and rats receiving mannitol and other long-chain sugars (10). These shifts can be accompanied by decreases in the urinary excretion of sodium, which often sets the stage for nephrocalcinosis The full potential of laboratory animal clinical chemistry has not yet been realized. Analytical chemistry can be applied to living systems with use of animal models in carefully controlled studies, to elucidate biochemical changes at the molecular level, to more fully elaborate long-term trends in healthy subjects, and to quantitate organism response to toxic changes in the environment.
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